Lawsuit charges weigh on Bayer profits again

February 28, 2013

(AP)—Charges for lawsuits over its birth control pills weighed on Bayer AG's earnings once again during the fourth quarter of 2012.

The German company said Thursday it made a of €374 million ($490 million) during the period, compared with €397 million the previous year.

The company booked €455 million in charges during the quarter due to current or anticipated lawsuits in the United States over claims of injuries from blood clots associated with its .

The profit fall masked a 7.3 percent rise in sales to €9.86 billion.

For the full year, net income declined 1 percent to €2.45 billion while sales rose 8.8 percent to €39.8 billion.

Aside from the problems with the contraceptives, the company said its business was doing well, with sales rising across the three basic divisions: prescription and over-the-counter drugs, farm chemicals and seeds, and such as polyurethanes, adhesives and coatings.

Excluding the lawsuit expenses, earnings before interest, taxes and other financial factors rose 9 percent to €8.24 billion.

Bayer has said it will raise its dividend for 2012 to €1.90 per share from €1.65 amid optimism over the coming year. It forecast a percentage increase in operating earnings in the mid-single digit range.

Bayer shares rose 2.6 percent to €75.71 in morning trading in Europe.

Explore further: Softbank 3Q profit doubles on iPhone sales

shares

Related Stories

Softbank 3Q profit doubles on iPhone sales

January 31, 2013
Japanese phone company Softbank, owned by billionaire Masayoshi Son, says its net profit more than doubled in the October-December quarter from a year earlier, helped by strong sales of Apple's iPhone and iPads.

Amgen 4Q profit drops 16 pct. on higher spending

January 23, 2013
Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop in fourth-quarter profit, as higher costs for production, marketing, research and other items offset higher sales for many of its biologic medicines. The results ...

J&J Q3 net income drops 7 percent on higher costs

October 16, 2012
Johnson & Johnson's third-quarter profit fell 7 percent as increased research and production costs offset higher sales for its medicines and medical devices and new revenue from its biggest acquisition ever.

Recommended for you

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

Team eradicates hepatitis C in 10 patients following lifesaving transplants from infected donors

April 30, 2017
Ten patients at Penn Medicine have been cured of the Hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease. The findings point to new strategies for increasing ...

'bench to bedside to bench': Scientists call for closer basic-clinical collaborations

March 24, 2017
In the era of genome sequencing, it's time to update the old "bench-to-bedside" shorthand for how basic research discoveries inform clinical practice, researchers from The Jackson Laboratory (JAX), National Human Genome Research ...

The ethics of tracking athletes' biometric data

January 18, 2017
(Medical Xpress)—Whether it is a FitBit or a heart rate monitor, biometric technologies have become household devices. Professional sports leagues use some of the most technologically advanced biodata tracking systems to ...

Financial ties between researchers and drug industry linked to positive trial results

January 18, 2017
Financial ties between researchers and companies that make the drugs they are studying are independently associated with positive trial results, suggesting bias in the evidence base, concludes a study published by The BMJ ...

Best of Last Year – The top Medical Xpress articles of 2016

December 23, 2016
(Medical Xpress)—It was a big year for research involving overall health issues, starting with a team led by researchers at the UNC School of Medicine and the National Institutes of Health who unearthed more evidence that ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.